What technology does Artrya Limited use?

Artrya utilizes AI-driven software to detect coronary artery disease, enhancing diagnostic efficiency through automation of CT angiography analysis. More information can be found on AYA.AX .

How has Artrya's stock performed recently?

AYA.AX recently surged by 12.9% to close at AUD 4.64, reflecting a significant year-to-date increase of 678% attributed to its AI capabilities in healthcare diagnostics.

What is the current Meyka AI rating for Artrya?

Meyka AI assigns a 'B' grade to AYA.AX with a total score of 66.7, recommending a 'HOLD' based on its comprehensive analysis of growth potential and market standing.

What price forecasts are available for Artrya?

Meyka AI projects a monthly target of AUD 4.44, with longer-term forecasts indicating a rise to AUD 8.41 over three years, demonstrating potential growth.

Is Artrya profitable?

Currently, Artrya reports a negative EPS of -0.18, indicating it is not yet profitable. However, its significant stock appreciation underscores investor optimism about future earnings growth.

AU Stocks

AYA.AX Stock Forecast December 2025: AI-Driven Growth Potential

ByHuzaifa Zahoor December 28, 2025December 28, 2025

Artrya Limited (ASX:AYA) has shown a remarkable rise of 12.9% to close at AUD 4.64 today. The company, specializing in AI-driven healthcare diagnostics, is capturing investor attention as it reaches new highs. Let’s dive into the factors shaping its future.